

- McKeown, T.: Validation of Screening Procedures, in *Screening in Medicine: Reviewing the Evidence: A Collection of Essays*. (London: Oxford University Press, 1968), pp. 1-13.
- McKeown, T., and E. G. Knox, The Framework Required for Validation of Prescriptive Screening, in *Screening in Medicine: Reviewing the Evidence: A Collection of Essays*. (London: Oxford University Press, 1968), pp. 159-173.
- McKeown, T., and C. R. Lowe: *An Introduction to Social Medicine*. (Philadelphia: F. A. Davis, 1966), pp. 86-87.
- Report of the International Conference on Adverse Reactions Reporting Systems*. National Academy of Sciences, Washington, D.C. 1971.
- Riggan, W. B., D. I. Hammer, J. F. Finklea, V. Hasselblad, C. R. Sharp, R. M. Burton, and C. M. Shy, CHESS, A Community Health and Environmental Surveillance System. *Proceedings of the Sixth Berkeley Symposium on Mathematical Statistics and Probability, vol. VI Effects of Pollution on Health*. (Berkeley: University of California Press, 1972), pp. 111-123.
- Sartwell, P. E. (ed.), *Maxcy-Rosenow Preventive Medicine and Public Health*, 9th ed. (New York: Appleton-Century-Crofts, 1965), pp. 16-19.
- Shapiro, S., P. Strax, and L. Venet. 1971. Periodic breast cancer screening in reducing mortality from breast cancer. *J. Am. Med. Assoc.*, 215:1777-1785.
- Terris, M. 1948. Relation of economic status to tuberculosis mortality by age and sex. *Am. J. Public Health*, 38:1061-1070.
- Thorner, R. M. 1969. Whither multiphasic screening? *New Engl. J. Med.*, 280:1037-1042.
- Thorner, R. M. and Q. R. Remein, *Principles and Procedures in the Evaluation of Screening for Disease*. U.S. Department of Health, Education, and Welfare. Public Health Monograph no. 67, 1961.
- White, K. L., T. F. Williams; B. G. Greenberg. 1961. The ecology of medical care. *New Engl. J. Med.*, 265:885-892.
- Whittenberger, J. L., The physical and chemical environment, in *Preventive Medicine*, edited by D. W. Clark, B. MacMahon, (Boston: Little, Brown, 1967), pp. 630-638.
- Wilson, J. M. G. November 1968.: The evaluation of the worth of early disease detection. *J. Roy. Coll. Gen. Pract., Suppl.*, 2:48-57.
- Winkelstein, W., Jr. 1972. Epidemiological considerations underlying the allocation of health and disease care resources. *Intern. J. Epidemiology*, 1:69-74.

Index

- Accidents:
 automobile, 74, 98-102, 197
 pedestrians fatally injured by, 98-102, 196
 epidemiologists' attention to, 202
 injuries from, 91
 prevention of, 98
- Adjustment, 13, 158-161
 direct, 159-161
 indirect, 159-161
- After-the-fact explanations, 118
- Age:
 adjustment, 13, 158-161
 current versus cohort tabulations, 54-58
 as factor in disease occurrence, 53-54, 99, 102, 109, 112, 197-198
- Age matching of controls, 92-93
- Age standardization (see Adjustment)
- Agent, disease-producing, 3, 68, 74
- Air pollution:
 in Berlin, New Hampshire, respiratory disease study, 80-83
 producing short-term time trends in disease, 67
 as related to urban-rural differences in lung cancer, 64
- Alcohol consumption:
 in relation both to disease and cigarette smoking, 165
 in relation to automobile accidents, 74, 98-99, 101-102, 196
 sex differences in, 58
 underestimation of, 36
- Alcoholism:
 as etiologic factor for head injuries and cirrhosis of liver, 166
 as etiologic factor for tuberculosis, 3
- Analysis of covariance, 161
- Analytic studies (see Studies)

- Angina pectoris (see Heart disease)
- Animals, findings in, as related to man, 3, 114
- Antibodies:
resulting from poliomyelitis vaccination, 128-130
as source of immunity, 68
- Arthritis, degenerative, 48-49, 54
- Associations between attributes and disease, 94, 150-151
(See also Statistical associations)
- Atherosclerosis:
biologic mechanisms in, 164
epidemiologic study of, 109-113, 118
spurious association with handgrip strength, 155
- Atrial fibrillation (see Heart disease)
- Attack rates, 67, 203
- Attributes:
qualitative, 13, 21, 94
quantitative, 13-21, 94
matching of, 93
- Autopsy:
coronary atherosclerosis at, 118
disease associations noted at, 166
in poliomyelitis vaccine trial, 129
- Average life expectancy (see Life expectancy)
- Berlin, New Hampshire, study of respiratory disease, 81-84
- Bias:
in case-control studies, 90, 92
in comparing invalid means, 24
in evaluating health-care innovations, 216
in experimental studies, 126, 136
in incidence studies, 104, 108-109
in medical literature, 198
in one's own study, 185
from poor quality data, 41
in sampling, 79
in therapeutic trials, 142
- Bilirubin breakdown due to light, 37
- Biostatistics (see Statistics)
- Blind experiments, 126-128
- Blood pressure:
absence of normal cutoff point in, 193
abstracting from medical records, 180-181
- Blood pressure:
age and, 93
comparison using quantiles, 20
in coronary heart disease, 13, 58, 84-85, 112-113, 141, 193-195
digit preference, 27-28
elevated (see Hypertension)
in Evans County, Georgia, study, 84-85
in Framingham Heart Study, 13, 112-113
in practicing preventive medicine, 194-195
as quantitative attribute, 13
sources of variation in, 25
stroke and, 38-42, 109
in study of observer error, 27
(See also Hypertension)
- Blood specimens and tests, 129, 131, 133, 194
- Bronchitis (see Chronic bronchitis)
- Cancer:
bias in a study of, 109
of bladder, 165
of breast, 54-55, 59, 62-63
screening for, 213
as cause of death, 117, 133
of colon, 6, 62-63, 167
family history of, 109
of lung, 3, 11-12, 64, 74-75, 163, 165, 208
screening for, 213
of prostate, 53
relationship to emotional state, 81, 92, 108
of skin, 58
of stomach, 8, 60, 62-63, 74, 208
of uterine cervix, 2, 59
(See also Leukemia)
- Cardiovascular disease, 117, 133, 192
(See also Heart disease; Hypertension; Peripheral vascular disease; Strokes)
- Case-control studies (see Studies)
- Case identification (ascertainment), 48, 88-90, 95
- "Cases" as term in research versus clinical setting, 88-89
- Cause-and-effect relationship, 121, 162-166

- Causation of disease, 1-5, 43-44, 58, 104, 108, 138, 162-166
- Causes of death, 32-34, 116-118
- Census tracts, 64, 66
- Cerebrovascular disease (see Strokes)
- Checkups, 2, 134-136, 216
- Cholesterol:
absence of normal cutoff point in, 193-194
changes in, 106, 108
comparison using quantiles, 20
in coronary heart disease, 20-21, 85, 106, 162, 193-195, 209, 215
in diet, 164, 209
in Evans County, Georgia, study, 85
in Framingham Heart Study, 24-25, 162
in practicing preventive medicine, 194-195, 209
in screening, 215
(See also Lipid levels in serum)
- Cholesterol phospholipid ratio, 20-21
- Chronic bronchitis, 58, 60, 82-83
- Chronic disease (conditions), 36-37, 67
epidemiologists' attention to, 202
- Cigarette smoking:
assessed by questionnaire, 34-35
avoidance of, by cooperative subjects, 134-135
in Berlin, New Hampshire, respiratory disease study, 81-84
as bias source in cancer study, 109
categories, 80
in chronic bronchitis, 58, 81-84
in coronary heart disease, 58, 113, 151-153, 163, 165, 193-195
in lung cancer, 3, 12-13, 64, 74, 150, 163, 165, 170
in oral contraceptive study, 97
in practicing preventive medicine, 194-195, 209-210
sex differences in, 58
statistical associations with, 150, 163, 165
urban-rural differences in, 64
- City, areas within, 64, 66
- Classification of diseases, 5-6
- Clinical history, 27, 34
- Clinical observations (see Observations)
- Clinical studies, 2, 138-148
- Clinician as source of hypotheses, 84
- Clinicians' views:
of data, 37-38, 42
of disease in the community, 210-211
of patients, 1-2, 5, 37-38
of screening, 213-214
of therapy, 142-143
- Cohort, 48, 86, 104-105, 107, 116, 119
- Cohort age tabulations (cohort analysis), 54-58
- Cohort studies (see Studies, incidence)
- Communicable period, 68, 70
- Computer data banks, 119
- Computer:
use with "canned" multivariate analysis program, 161
use in data processing, 184
- Confidentiality of records, 122
- Congenital defects:
epidemiologic study of, 202
monitoring of, 206
- Consultation in carrying out a study, 173-174
- Contraceptives, oral and thromboembolic disease, 95-98, 164
- Control group, 48
in experimental studies, 121-136
nonrandom, 124-125, 131-133
randomized, 123-125, 131, 133
matched controls, 92-93, 96-97, 99-100
need for, in claiming treatment benefits, 196
"paired" selection of, 93
selection of, 90-93, 96-97, 99-100
- Cooperation of experimental subjects, 125-126
- Coronary care units, 53, 148
- Coronary heart disease (see Heart disease)
- Coroner's reports, 112
- Correlation:
built-in, 109
coefficient of, 151-152
ecological, 153
multiple, 161
- Counts, 7-8, 13-14
- Critical reading (see Literature)
- Cross-sectional age tabulations, 54-58
of life expectancy 57-58, 117
- Cross-sectional studies (see Studies, prevalence)

- Crowding:
and rheumatic fever, 67
and tuberculosis, 3
- Cycles of disease occurrence, 73-74
- Data analysis:
in case-control studies, 94
in incidence studies, 107-108
for one's own study, 181-184
in prevalence studies, 80
- Data banks, 119
- Data collection:
in case-control studies, 93-94
forms, 174-179, 181
pre-coded, 177
in incidence studies, 105-107
methods for one's own study, 174-181
pretesting of, 179-181
in prevalence studies, 79-80
- Data processing for one's own study,
174-175, 183-184
(See also Computer)
- Data quality, 24
- Death:
age at: mean, 19
median, 19, 117
causes of, 32-34, 116-118
as outcome of disease,
138-139
sudden (see Sudden death)
surveillance of, 106
- Death certificates, 32, 38, 112, 116, 135
- Death rates (see Mortality rates)
- Deciles, 19
- Definition of diseases, 5-6
- Definition of problem to be studied;
169-170
- Denominators:
as central concerns of epidemiology, 8
changing, 11
lack of, in spontaneous reporting
systems, 206
need for, in statements about risk,
196-198
person-year, 107-108
population, 66
in rates or proportions, 8
- Dental caries, 53, 131-133
- Descriptive studies (see Studies)
- Diabetes mellitus, 32, 58, 96, 113,
141-142, 175
- Diabetes mellitus:
screening for, 212, 214-215
- Diagnosis:
as observations or data, 30, 32
as related to apparent disease
associations, 166
- Diagnoses:
criteria for, 30, 83, 85, 89, 112, 126, 130
early, and survival, 148
epidemiologic aids to, 187-189
epidemiologic (analytic) studies to
improve, 189-191
- Diet:
for changing risk factors, 113, 195
high animal fat, 84, 164
in Japan, 62
- Dietary history, 85
- Digit preference, 27-28
- Disability:
in multiphasic evaluation study,
135-136
as outcome of disease, 138-139
- Discriminant analysis, 161
- Disease:
causation (see Causation of disease)
duration (see Duration of disease)
in elderly persons, 53, 113
monitoring frequency changes, 206
names, descriptive versus causal, 5-6
onset times, 67
outcome, 138-148
prognosis, 139-140
reporting, 31
- Distributions, 14-22
cumulative, 14-16, 18-20
display of, 15-16
normal or Gaussian, 191
overlapping of, in healthy and sick
persons, 192-193
- Double-blind experiments, 126-127
- Droplet nuclei, 68
- Droplets, 68, 74
- Drugs:
abuse of, 36, 216
adverse reactions to, 31, 126, 144, 177,
204-207
monitoring of, 205-207
cohort exposed to, 105
effects on laboratory tests, 37
in experimental studies, 126, 142, 144,
196

- Drugs:
physician's evaluation of, 142
in practicing preventive medicine, 195,
209
to prevent atherosclerosis, 113
recording reasons for administration,
177-178
therapeutic trials of, 142, 144, 196
in treating hypertension, 144, 195
- Dummy (see Placebo)
- Duration of disease, 80-81, 108
in incidence studies, 108
in prevalence studies, 80-81
- Duration of follow-up in incidence
studies, 106-107
- Ecological correlations, 153
- Education:
background of subjects of
case-control study, 91
as index of socioeconomic status, 60,
85
- Elderly persons' diseases, 53, 113
- Electrocardiogram, 85, 111
abnormalities of, 113
in diagnosing heart disease, 189
logistical problems in obtaining, 180
- Environment, 3, 23, 62, 109, 140, 209
changes to prevent disease, 209-210
hazards in, 34
detection and evaluation of, 204-207
- Epidemics, 31, 67-75
as appropriate labels for long-term
trends, 74-75
duration of, 70
investigation of, 201-204, 206
point source, 70
time pattern of, 70
- Ethical problems:
in experimental studies, 122-123, 127
in intentional exposure to radiation,
114
in observational studies, 122
in screening, 212
- Etiology (see Causation of disease)
- Evans County, Georgia, study of
cardiovascular disease, 84-86, 105
- Examinations:
to detect disease in a population, 79,
85, 105, 111, 133, 180
- Examinations
physical, 27-28, 111, 119, 129, 134-136
- Exercise (see Physical activity)
- Experimental (treated) group, 121-136
- Experimental studies (see Studies)
- Familial aggregation, 111
- Family history:
of cancer, 109
of coronary heart disease, 113
"Fishing expeditions," 103
- Fluoride and dental caries, 53, 131-133,
209
- Follow-up:
of patients with disease, 140-144
of persons screening positive, 215
of population for disease development,
48, 105-110, 112, 118
of subjects in an experiment, 121, 135
variable periods of, 107
- Food:
contaminated, 70, 203
as vehicle of disease transmission, 68,
73
- Framingham Heart Study, 38, 109-115,
162
- Gallbladder disease, 113, 171, 190
(See also Gallstones)
- Gallstones, 9, 44-45, 58, 171
- Genetics:
and disease, 58-59
and migration, 62
(See also Inheritance)
- Geographic variation in disease
occurrence, 152-153
(See also Place)
- Glucose, 194
method for recording serum level,
175-176
- Groups:
of individuals versus groups of groups,
152-153
patient versus population, 138-139
study of, 1-2
- Headache:
as descriptive disease name, 5
relation to hypertension, 190
- Health-care professional (see Clinician)

- Health services research, 202, 217
- Heart disease:
- angina pectoris, 36, 85, 113, 141, 170
 - atrial fibrillation, 24
 - as cause of death, 32
 - congestive heart failure, 50-51, 145
 - coronary: duration of, in prevalence studies, 80, 105
 - in Evans County, Georgia, study, 84-86, 105
 - in Framingham Heart Study, 20-21, 109-114, 162
 - incidence of, 118
 - in incidence studies, 105-106, 118
 - in Japanese, 62-63
 - mortality and cigarette smoking, 151-153
 - multivariate methods in study of, 161
 - need for epidemiologic study, 2
 - in practicing preventive medicine, 194-195, 209
 - psychological factors in, 170
 - relation to aging, 53-54
 - relation to race, 84-86
 - relation to sex, 58
 - risk factors, 20-21, 58, 109-114, 151-153, 193-195, 215
 - risk screening, 215
 - spurious association with handgrip strength, 155
 - statistical associations with, 162-166
 - diagnosis of, as aided by epidemiology, 188-189
 - myocardial infarction, 3-5, 53, 85, 113, 141, 148, 170, 197, 215
 - rheumatic, 60, 113, 140
 - (See also Rheumatic fever)
 - scleroderma, 147
- Heat waves producing short-term time trends in disease, 67
- Hepatitis, 8, 70-73
- Hernias, 91-92, 167
- Herniorrhaphy, 49, 92
- Histogram, 15-16
- Hospital charts (records), 51, 89
- Hospitalizations in population follow-up, 106, 112, 135
- Host (of disease), 3, 68, 74, 98
- Hyaline membrane disease, study of factors predicting outcome, 141
- Hypertension:
- in coronary heart disease, 112-113, 215
 - effects of detecting, 136
 - effects of treating, 144-145
 - in Evans County, Georgia, study, 84
 - in Framingham Heart Study, 112-113
 - in incidence studies, 118
 - in Japanese, 62
 - in mortality statistics, 32-34
 - predisposing to thromboembolism, 96
 - racial differences in, 59
 - recording history of, 181
 - socioeconomic status in, 60
 - in stroke, 38-42
 - symptoms of, 190
 - Veterans Administration study of, 144-145
 - (See also Blood pressure)
- Hypotheses for further study:
- from case-control studies, 103
 - from descriptive studies, 53-54, 59
 - from physicians' observations, 84
- Immunity, 68
- duration of, 53
 - to tuberculosis, 56
- Immunization, 68-70, 208
- Inapparent infections, 68
- Incidence rates (see Rates)
- Incidence studies (see Studies)
- Incubation period, 68, 70, 203
- in chronic noninfectious diseases, 110
- Infant mortality, 60-61, 133
- Infections:
- transmission of, 68
 - upper respiratory, 74
- Infectious disease, 3, 67-74
- epidemiologists' attention to, 201-202
 - investigation of epidemics, 201-204
- Informed consent, 123
- Inheritance, sex-linked, 58
- (See also Genetics)
- International Classification of Diseases*, 32
- International comparisons of disease or mortality rates, 61-64
- Interpretation:
- of case-control studies, 94-95
 - of prevalence studies, 80-81

- Interquartile range, 20
- Interviews:
- to collect data, 36, 82, 90, 94, 96-97, 99-101, 180, 202-203
 - to rule out disease in control subjects, 93
- Japan:
- breast feeding in, 62
 - diet in, 62
 - uniqueness of, regarding certain diseases, 61-64
- Japanese, epidemiologic study of, in three areas, 64
- Kaiser-Permanente Medical Care Program (Kaiser Foundation Health Plan), 34-36, 134-135, 207
- Kidney disease:
- absence of, after poliomyelitis vaccination, 131
 - nephritis, 32-34
 - renal calculi, 89, 92-93
 - renal colic, 89
 - scleroderma, 147
- Laboratory data, 37
- collection in case-control studies, 93
- Laboratory tests, 38, 111, 189
- in discriminating diseased from well, 189, 191-194
 - sensitivity of, 192
 - specificity of, 192
- Leukemia, 105, 117
- Life expectancy, 57-58
- Life-insurance-company investigations, 105
- Life-span and radiation, 114, 117
- Life table, 57-58
- method for determining survival curves, 147
- Lipid levels in serum, 111-113, 164
- (See also Cholesterol)
- Literacy and birthplace, 153
- Literature:
- critical reading of, 195-200
 - reviewing for a study, 170-171
- Liver, cirrhosis of, 9, 58, 143, 165-166
- (See also Hepatitis)
- Loss to follow-up, 107, 109
- Luau, as source of hepatitis epidemic, 72-73
- Lung disease:
- obstructive, 82
 - scleroderma, 146-147
- Mai-tai punch as hepatitis vehicle, 73
- Marital status and disease occurrence, 53, 59
- Matched controls, 92-93
- Means, 16-17, 19, 22, 24-25, 94, 179
- comparison of, 24-25
- Measles epidemic, 68-70
- Medians, 18-19, 94, 117
- advantages over means, 19
- Medical care:
- emergency, 102
 - limited effects on community health, 207-209
 - new system of, 216
 - studies of, 202
 - (See also specific programs and plans)
- Medical chart (see Medical records)
- Medical (clinical) history, 27, 85, 111, 129
- Medical records, 30-31, 51
- problems in abstracting, 180-181
 - for ruling out disease in control subjects, 93
- Medical specialists' observations, 28-30
- Medicine, as a complex field, 118
- Menopause, 54, 58-59
- artificial (surgical), 59
- Mental illness, as object of epidemiologic study, 202
- Migration, 62
- Misclassification of study subjects, effects of, 41-42, 89
- Morbidity ratios, 12-13, 20-21, 160
- Mortality:
- infant, 60-61, 133
 - influence of checkups on, 134, 136
 - life insurance investigations of, 105
 - operative and postoperative, 148
 - radiation exposure and, 114-117
 - rates, 10, 32-33, 61-62
 - and life expectancy, 57-58

- Mortality
and marital status, 59
ratios, 12, 117, 160
statistics, 32-34, 61
from tuberculosis, 55-57
- Multiphasic Health Checkup Evaluation Study, 134-136, 212
- Multiphasic screening (see Screening)
- Multiple correlation, 161
- Multiple logistic method, 161
- Multiple regression, 161
- Multiple Risk Factor Intervention Trial, 113
- Multiple sclerosis, North-to-South gradient in, 64-65
- Multivariate analysis, 161
- Myocardial infarction (see Heart disease)
- National Health Survey, 36-37
study of hypertension symptoms, 190
- National Heart and Lung Institute, 112
- National Institutes of Health, 113
research grant applications, 172
- Natural experiments, 46
- Natural history of disease, 139-140
- Nephritis (see Kidney disease)
- Newburgh-Kingston (N.Y.)
Caries-Fluorine Study, 132-133
- Nonresponse:
in Framingham Heart Study, 110-111
to questionnaires, 34
- Normal values, 191-194
definitions of, 191
determination of normal limits, 191-194
- North-to-South gradient of multiple sclerosis, 64-65
- Numerator cases, 66
- Numerator data, 196-197
- Nutritional-deficiency diseases and socioeconomic status, 60
- Obesity, 19, 44-45, 48-49, 58, 113, 194-195
- Objectivity of authors, 199
- Observational studies (see Studies)
- Observations:
clinical, 26-28, 109
in epidemiology, 23-42
- Occupation, 53, 60, 85-86
- Occupational exposures, 82
- Oral contraceptives (see Contraceptives)
- Osteoarthritis (see Arthritis, degenerative)
- Outbreak (see Epidemics)
- Pain, low back, in example of spurious relationship, 156-157, 159-160
- Pasteurization of milk in preventing disease, 209
- Pathologists' observations, 28
- Patient care, 1
relation to epidemiology, 187-200
- Percentages, 8
- Percentiles, 19-20
- Periodic time trends (see Time pattern of disease occurrence)
- Peripheral vascular disease in
Framingham Heart Study, 111
- Person, personal characteristics and disease, 52-60
- Person-to-person spread of disease, 68, 70, 74
- Person-years of observation, 107-108, 116
- Pesticide:
cohort exposed to, 105
as environmental hazard, 204
- Phthisis, as tuberculosis manifestation, 6
- Physical activity, 86, 113, 209
- Physical examinations (see Examinations)
- Physician (see Clinician)
- Place, location of disease occurrence 52, 60-67, 152-153
- Placebo:
in antihypertensive drug trial, 144
in poliomyelitis vaccine trial, 128-130
- Placebo effect, 142, 196
- Poliomyelitis 45-46, 60, 128-131
vaccine trial, 128-131
- Population at risk, 9-11, 86, 105, 111
(See also Denominators)
- Portacaval shunt operation (Boston Interhospital Liver Group Study), 143-144
- Post hoc explanations, 118
- Prediction of study outcomes, importance of, 117-118

- Pregnancy, 58-59, 95-97
- Prevalence:
as determined by incidence and duration, 81
of disease as related to results of screening, 214-215
- Prevalence cases, 81
- Prevalence rates (see Rates)
- Prevalence studies (see Studies)
- Prevention of disease, 1, 5, 6, 98, 114, 122-126, 134, 138-139, 194-195, 209-210
by large-scale social and environmental change, 209-210
prevention of accidents, 98
- Preventive medicine, 122
office practice of, 194-195, 209-210
- Probability, 26
- Probability (*p*) values, 26
- Prognosis of disease, 139-141
- Proportions, 8, 13-14, 21, 139
- Prospective studies (see Studies)
- Protocol for a study:
contents of, 172-173
later use of, 185
necessity for writing, 171-172
preparation of, 171-173
- Psychology, as complex field, 118
- Psychosocial factors, 113
study of, 170
- Pulmonary embolism (see Thromboembolic disease)
- Pulmonary function, 83
tests of, 82
vital capacity, 113
- Qualitative attributes (see Attributes)
- Quantiles, 18-20, 22
- Quantitative attributes (see Attributes)
- Quartiles, 19-21, 108
- Questionnaires, 34-36, 38, 82, 134
overreporting of disease symptoms, 35-36
response and nonresponse, 34-36
standardized respiratory, 82
use in office practice, 194
- Quintiles, 19
- Race, as factor in disease occurrence, 53, 58-59, 66-67, 84-86, 162
- Racial differences:
in coronary heart disease, 84-86
in hypertension, 59
in rheumatic fever, 66-67
in sickle-cell anemia, 58
in skin cancer, 58
- Radiation exposure, 46, 81, 105
ethical problems, 114
groups exposed and studied, 115
maternal, 81, 114-117
problems in determining, 180
- Radiologists, 28-29
observations of, 28-29
mortality in, 114-117
- Random numbers, 78
- Random samples (see Samples)
- Randomized control groups in experiments, 123-125, 131, 133, 143-144
- Ranges of distributions, 18
interquartile (see Interquartile range)
- Ranking of individuals in a group, 19, 24-25
- Rapport with community in specific studies, 84, 112
- Rates, 8-13, 21
age-adjusted, 159-161
age-specific, 10, 161
attack, 67, 203
case fatality, 10
comparison of, 11-13, 21
cure, 145
differences in, 11-12, 21
disability, 145
expected, 12-13, 160
incidence, 9, 21, 81, 106-107, 118, 203
maternal mortality, 11
as measures of disease outcomes, 145
mortality or death, 10, 32-33, 99, 145
other, 9-11
period prevalence, 9-10
prevalence, 8-9, 21, 81, 145
ratios of, 12-13, 21
recovery, 145
survival, 145
- Ratios:
morbidity, 12-13, 20-21, 160
mortality, 12, 117, 160
of rates (see Rates)
risk, 12
- Record-linkage, 119

- Regional comparisons within countries, 64-65, 152-153
- Registrar General for England and Wales, 60
- Relationships, 37-45, 77, 119
detection of, in poor quality data, 38-42
linear, 151
- Relative risk (see Risk of disease)
- Reliability of observations, 24-25, 27, 30
- Religion, 53
- Respiratory disease, chronic, 81-83
- Retrospective studies (see Studies)
- Rheumatic fever, 3, 64, 66-67, 140
- Risk of disease, 104, 107, 113
gradient of, 165
need for denominator to determine, 196-198
relative, 12, 94, 163
from case-control studies, 94, 97
- Risk factors, 109, 112-114
combinations of, 113
- Rural areas, 64, 110
providing health care to, 216
- Salt, dietary, 62
- Sample size determination, 127
- Samples:
cluster, 78-79, 82
random, 26, 82-83, 85, 135
simple random, 78, 82
stratified random, 78, 82, 85
systematic, 79, 82, 110, 135
(See also Sampling)
- Sampling:
of families, 111
by households, 79
methods of, 78-79
in multiple stages, 79, 82
in selecting control groups, 92
- Sampling variation, 25-26, 38, 92, 127
- Scleroderma, survival with, 146-147
- Screening, 211-216
for high risk, 215
multiphasic, 34, 212, 215-216
expanding role of, 215-216
- Seasonal variation in disease occurrence, 3, 73-74, 206
- Secular trends, 67, 74-75
- Selection:
of data to prove a point, 199
of papers for publication, 199-200
- Self-selection, 117, 126
- Sensitivity of a test:
definition of, 192
in screening, 213-214
- Sequential analysis, 127-128
- Sex, as factor in disease occurrence, 53, 58, 83-85, 112, 155
- "Shoe-leather" epidemiology, 99
- Smoking (see Cigarette smoking)
- Social change to prevent disease, 209-210
- Social class (see Socioeconomic status)
- Socioeconomic status, 85
as factor in disease occurrence, 53, 59-60, 66-67, 85-86, 116
and infant mortality, 60-61
- Specifications of variables in data analysis, 158
- Specificity of a test:
definition of, 192
in screening, 213-214
- Spouse pairs, 111
- Standard deviations, 17-18, 20, 22, 94, 179
- Standardization (see Adjustment)
- Statistical associations, 150-167
as cause-and effect relationships, 162-166
consistency of, 163-165
due to chance, 154
between diseases, 151, 166-167
general applicability of, 162
measures of, 150-151
specificity of, 165-166
spurious or secondary, 154-161, 163-164, 170
control of, in data analysis, 158-161
prevention of, 157-158
strength of, 163
time sequence of, 163
- Statistical methods for multiple variables, 161
- Statistical significance:
versus biological significance, 154
tests of, 17, 26, 123, 154
- Statistics, 13-14
(See also Vital statistics)
- Stomach ulcer (see Ulcer)

- Strata (stratification) of populations, 78-79, 124
- Stratified samples (see Samples)
- Strokes:
decubitus ulcers after, 140
diagnosing, in incidence studies, 106, 109
in Framingham Heart Study, 111, 113
hypertension and, 39-42, 144
in Japanese, 62-63
mental status following, 92
oral contraceptives and, 98
questionnaire versus neurologists' diagnosis, 38
in Veterans Administration study, 144
- Studies:
analytic, 46-47, 88, 102, 140-142
case-control, 46-50, 77, 88-103, 108, 140-141, 163, 203
descriptive, 46-47, 52-76, 84, 109, 139
to evaluate changes in health care, 216-217
experimental, 44-46, 113-114, 121-137
blind, 126-128
double-blind, 126-127
exploratory, 103
how to carry out, 169-186
how to report results of, 184-186
incidence, 46, 48-50, 77, 80, 86, 94-95, 104-121, 140, 163, 203
observational, 44-46, 104, 113, 121-122
prevalence, 46-50, 77-86, 88-90, 94-95, 105, 107-108, 140, 163
as first stage of incidence study, 86, 105
prospective, 46, 49-51, 104, 118-119
retrospective, 46, 49-51, 115, 119
retrospective cohort (retrospective incidence), 115, 119
retrospective-prospective, 50
types of, 43-51
- Sudden death, 62, 80, 113, 170
- Surveys:
household, 36-37
National Health Survey, 36-37, 190
- Survival, 145-148
duration of, 145-146
expected, 147
rates of, 145
starting times for determining, 148
- Survival curves, 146-148
by actuarial or life-table method, 147-148
- Susceptible persons (to disease), 68, 70
- Symptoms and disease diagnosis, 189-191
- Tables:
blank, as aid in data analysis, 181-182
complete, 182-183
fourfold (two-by-two), 39-40, 154
incomplete, 182
preparation of, 181-183, 185-186
- Terciles, 19
- Therapeutic trials, 142-145
- Therapy, enthusiasm over, 143
- Thromboembolic disease, 95-98, 164
- Thrombophlebitis (see Thromboembolic disease)
- Time pattern of disease occurrence, 67-75, 153
assessing time trends by prevalence studies, 84
long-term (secular) trends, 67, 74-75
periodic trends, 67, 73-74
short-term trends, 67-73
- Time sequence of factors and disease, 49-50, 81, 108
- Tobacco (see Cigarette smoking)
- Tooth decay (see Dental caries)
- Tooth enamel, mottled, 131, 133
- Traumatic injuries, 97-98
- Tuberculosis:
BCG vaccination, 44-45
causal versus descriptive names for, 6
causation of, 3
on chest x-rays, 29-30
cohort versus cross-sectional age trends, 55-57
decline in mortality from, 5, 207
social class gradient, 60
study in Framingham, 110
variety of manifestations, 166
- Typhoid carriers, detecting, 204
- Ulcer:
decubitus, 140
peptic, 165
stomach, 60

- U.S. Public Health Service, 110
- Upper respiratory infections, 74
- Urban areas, 64
- Uric acid distribution, 15-18

- Vaccination, 204
 - BCG, 44-45
 - poliomyelitis, 45-46, 128-131
(See also Immunization)
- Vaccine, 2-3, 45
- Validity of observations, 24-25, 38
- Variables:
 - dependent, 44-45
 - dichotomous, 39
 - independent, 44-46
 - qualitative, recording of, 176-179
 - quantitative, 13-21, 94, 151
 - matching of, 93
 - recording of, 175-176, 179
 - relationships between, 44-45, 151
- Variations in measurements, 25-26
 - within an individual, 25
 - among individuals, 25
 - measurement errors, 24-25
 - due to sampling, 25-26
 - among subgroups, 25
- Vectors, 68, 74
- Vehicles of disease transmission, 68

- Venereal disease, 31, 36, 53
- Veterans Administration study of hypertension therapy, 144
- Vital statistics, 61, 133
 - surveillance of, 206
- Volunteers, 134, 162
 - in Framingham Heart Study, 111, 162

- Water, as vehicle of disease transmission, 68, 74
- Water supplies:
 - contaminated, 70, 204
 - fluoride in, 53, 131-133, 209
- Waterborne gastrointestinal infections, 74
- Weather and traffic accidents, 101-102.
- Web of causation, 3-5
- Whooping cough, decline in mortality from, 208

- X-rays, 29-30
 - chest, 29-30, 85, 111, 188-189
 - dental, 132-133
 - gallbladder, 190
 - knee, 48-49
 - showing renal stones, 89
 - (See also Radiation exposure; Radiologists)